메뉴 건너뛰기




Volumn 19, Issue 7, 2001, Pages 767-778

Cost effectiveness of becaplermin in the treatment of diabetic foot ulcers in four European countries

Author keywords

[No Author keywords available]

Indexed keywords

BECAPLERMIN;

EID: 0034922872     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200119070-00005     Document Type: Article
Times cited : (60)

References (18)
  • 8
    • 0032771893 scopus 로고    scopus 로고
    • ADA Consensus development conference on diabetic foot wound care
    • (1999) Diabetes Care , vol.22 , pp. 1354-1360
  • 10
    • 0032720053 scopus 로고    scopus 로고
    • Efficacy and safety of Becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: A combined analysis of four randomized studies
    • (1999) Wound Rep Reg , vol.7 , pp. 335-340
    • Smiell, J.M.1    Wieman, T.J.2    Steed, D.L.3
  • 11
    • 0034505166 scopus 로고    scopus 로고
    • The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex®): A core model with an application using Swedish data
    • (2000) Value Health , vol.3 , pp. 1-8
    • Persson, U.1    Willis, M.2    Ödegaard, K.3
  • 13
    • 0019803407 scopus 로고
    • The dysvascular foot: A system for diagnosis and treatment
    • (1981) Foot Ankle , vol.2 , pp. 64-122
    • Wagner, F.W.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.